PREVALENCE AND RISK FACTORS OF BRONCHO-OBSTRUCTIVE SYNDROME IN YOUNG CHILDREN
##article.abstract##
Relevance of the topic: The article is devoted to the clinical and pharmacological audit of the use of antibiotics in the treatment of broncho-obstructive syndrome (BOS) in premature infants living in the Aral Sea region, using the Republic of Karakalpakstan as an example. Broncho-obstructive syndrome is one of the most common and clinically significant problems among premature infants today. According to a retrospective analysis, the frequency of CF in patients is 1.9% of the total number of children with bronchopulmonary pathology in Tashkent, 1.0% in the Khorezm region and 1.0% in the Republic of Karakalpakstan. Among the social risk factors that have the greatest impact on the development of cystic fibrosis in children, marriage between relatives is considered (26.6%). The main factors aggravating the course of the pathology are: medical and biological factors - complicated pregnancy (91.1%), diseases during pregnancy (73.3%), anemia of I-II degree during pregnancy (100.0%), aggravated premorbid background in the child (anemia of I-II degree - 100.0%, AEE - 91.6%, residual complications of rickets - 63.8%, atopic dermatitis - 91.6%).
##submission.citations##
1. Zaitseva O. V. Broncho-obstructive syndrome in children with acute respiratory diseases: modern aspects of therapy // Consillium Medicum. - 2003.
2. Krivopustov S. P., Shcherbinska K. M. Cough in children: causes, diagnostics, treatment // Children's doctor. - 2009. - № 2
3. Lasitsa O. L., Lasitsa T. S., Nedelskaya S. M. Childhood allergology. - K.: "Book plus". - 2004.
4. Mizernitsky Yu. L. Diagnostics and principles of therapy of acute bronchial obstruction in children // Consilium medicum. Pediatrics. - 2008. - № 1.
5. Okhotnikova E. N. Bronchial obstruction syndrome of infectious and allergic genesis in young children and mucolytic therapy // Child health. – 2007. – No. 3
6. Senatorova A.S. Differential diagnostics of broncho-obstructive syndrome in children // Health of Ukraine. - 2007. - № 18/1.
7. Nelson Textbook of Pediatrics. Robert M. Kliegman, Richard E. Behrman, Hal B. Jenson, Bonita F. Stanton, 18th edition, Saunders, 2007.
8. The Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2010. http://www.ginasthma.org.
9. Knyazheskaia N.P. Leukotriene receptor antagonists - anti-inflammatory drugs for the treatment of bronchial asthma. Asthma and allergy. 2014; 1: 8-10.
10. Global strategy for the treatment and prevention of bronchial asthma. Revision 2006. Translated from English. Ed. by A. G. Chuchalin. Moscow: Atmosphere. 2007. 256 p.
11. Berezovsky A. S., Nezabudkin S. N., Antonova T. I., Nezabudkina A. S. The place of the leukotriene receptor antagonist (montelukast) in the therapy of mild persistent asthma. Russian Medical Journal. 2010; 924: 1450–1452.
12. Vasilevsky I. V., Skepyan E. N. Experience with montelukast in the treatment of bronchial asthma in children. Pediatric Pharmacology. 2007; 2 (4): 15–21.
13. Baranova I. A. Modern possibilities of using anti-leukotriene receptors in the treatment of bronchial asthma in adults. Pulmonology. 2014; 1: 91–96.